Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell® in a Mass Casualty Scenario

NEW YORK, May 10, 2017 /PRNewswire/ -- Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emerge...